Ruxolitinib and Tocilizumab for Child Bronchiolitis Obliterans After Toxic Epidermal Necrolysis
- 12 March 2026
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 157 (4)
Abstract
Toxic epidermal necrolysis (TEN) is a life-threatening mucocutaneous disorder with rare but potentially fatal respiratory complications. We present an exceptional documented case of TEN with severe bronchial obstruction successfully treated with tocilizumab and ruxolitinib in an 11-year-old patient. Despite early methylprednisolone pulse therapy, a repeat bronchoscopy showed progressive obstruction of proximal bronchial lumen by synechiae and mucosal membranes. Following multidisciplinary discussion, treatment was intensified with tocilizumab and ruxolitinib, resulting in marked respiratory improvement and decreased proinflammatory cytokines in bronchoalveolar lavage. No adverse effects were observed during 8 months of follow-up. Recent research supports Janus kinase inhibitors as targeted therapy in TEN.Keywords
This publication has 14 references indexed in Scilit:
- Diagnosing and Managing Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017–2023Journal of Investigative Dermatology, 2025
- Spatial proteomics identifies JAKi as treatment for a lethal skin diseaseNature, 2024
- Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 studyThe Lancet Haematology, 2024
- Respiratory complications in pediatric epidermal necrolysis: A retrospective study of 22 casesJournal of the American Academy of Dermatology, 2023
- End-Stage Respiratory Failure Secondary to Bronchiolitis Obliterans Syndrome Induced by Toxic Epidermal Necrosis, Also Known as Lyell Syndrome: A Case ReportTransplantation Proceedings, 2021
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 2020
- IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysisAnnals of Hematology, 2020
- Bronchiolitis obliterans as a long‐term sequela of Stevens–Johnson syndrome and toxic epidermal necrolysis in childrenClinical and Experimental Dermatology, 2019
- Severe cutaneous adverse reactions to drugsThe Lancet, 2017
- Airway inflammation in children and adolescents with bronchiolitis obliteransCytokine, 2015